Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Stanford University School of Medicine, Palo Alto, California